Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06817161 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:

Study acronym: ESTANVO
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site contacts updated at 1 of 4 sitesv3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 24, 2025 to Apr 30, 2025
    • Site details revised at 4 of 4 sites
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Impact of stimulation of parasympathetic activity by transcutaneous auricular vagus nerve stimulation (taVNS) on quality of life (QoL) relating to digestive symptoms in patients undergoing first-line treatment for ovarian cancer, as compared to shame taVNS
Trial Details
NCT Number NCT06817161
Lead Sponsor Centre Francois Baclesse
Conditions
(from sponsor)		 Ovarian Carcinoma, First Line Chemotherapy, Digestive System Disorders
Related terms Digestive System Diseases, Ovarian Neoplasms
Enrollment 116 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov